Physician profile
Alexander Doan
NPI 1780204651
$3,049.39
in general payments reported to CMS, 2019-2025
36 companies · $2,736 in 2025
The $2,736 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $314 · 2025: $2,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $357.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $311.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.88 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.10 | 2024-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $171.40 | 2024-2025 | |
| Radius Health, INC. | $165.51 | 2025 | Tymlos |
| Amgen INC. | $154.19 | 2025 | Repatha, Otezla, Evenity |
| Genzyme Corporation | $139.79 | 2025 | |
| Gilead Sciences, INC. | $122.41 | 2025 | |
| Ibsa Pharma INC. | $107.11 | 2025 | Flector, Licart, Tirosint |
| Exact Sciences Corporation | $97.81 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $88.35 | 2024-2025 | |
| Lundbeck LLC | $87.95 | 2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $87.45 | 2025 | Rexulti |
| Lilly USA, LLC | $72.05 | 2024-2025 | Kisunla, Zepbound, Mounjaro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $67.68 | 2025 | Zenpep |
| Ucb, INC. | $59.51 | 2025 | Nayzilam, Rystiggo |
| Insulet Corporation | $59.11 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $40.36 | 2025 | |
| Edwards Lifesciences Corporation | $37.52 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $34.58 | 2025 | Gvoke Hypopen, Keveyis |
| Axsome Therapeutics, INC. | $34.40 | 2025 | Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.10 | 2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $30.86 | 2025 | Ponvory |
| Tandem Diabetes Care, INC. | $28.39 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $27.84 | 2025 | |
| Springworks Therapeutics, INC. | $27.54 | 2025 | Gomekli |
| Dexcom, INC. | $24.64 | 2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $21.46 | 2025 | Yorvipath |
| Optinose US, INC. | $20.09 | 2025 | |
| Glaxosmithkline, LLC. | $19.38 | 2024 | Shingrix, Arexvy |
| Azurity Pharmaceuticals, INC. | $18.95 | 2025 | Azmiro |
| Dynavax Technologies Corporation | $18.22 | 2025 | Heplisav-B |
| Recordati_rare_diseases_inc. | $17.05 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $15.95 | 2025 | Gardasil 9, Capvaxive |
| Evoke Pharma, INC. | $15.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.